参考文献/References:
[1]WANG G,ZHANG X,LIU Z.Development of a neutral plane in PHC-Supported embankments over soft soils:A case study of a motor-racing circuit[J].Int J Geomech,2024,24(2):16.
[2]FAN J,XU J,MA Q,et al.Silylene-stabilized neutral dibora-aromatics with a B=B bond[J].J Am Chem Soc,2024,146(29):20458-20467.
[3]石磊,安梓铭,冯琴.联合检测血清AFP、AFP-L3%和PIVKA-Ⅱ水平早期诊断和判断原发性肝癌患者预后临床价值探讨[J].实用肝脏病杂志,2023,26(3):404-407.
[4]滕达,许悦,张萌,等.AFP、AFP-L3和PIVKA-Ⅱ联合检测在肝细胞肝癌诊断中的应用价值[J].肝胆外科杂志,2024,32(1):29-34.
[5]彭万宏,门秀丽,宋浩.CT影像学联合血清甲胎蛋白、Hsp90α、铁蛋白检测对肝细胞肝癌的临床诊断价值[J].临床和实验医学杂志,2022,21(23):2555-2558.
[6]彭美蓉,伍丽,薛芳芳,等.血清Hsp90α、AFP、Gpc3在原发性肝癌早期诊断中的临床应用[J].中西医结合肝病杂志,2022,32(10):920-923.
[7]中华人民共和国国家卫生健康委员会医政司.原发性肝癌诊疗指南(2024年版)[J].肿瘤综合治疗电子杂志,2024,31(2):277-334.
[8]中华医学会消化病学分会,谢渭芬,唐承薇,等.中国肝硬化临床诊治共识意见[J].临床肝胆病杂志,2023,39(9):2057-2073.
[9]张强,王志飞,谢雁鸣,等.基于数据挖掘中医药治疗原发性肝癌的用药规律研究[J].空军军医大学学报,2022,43(7):751-755.
[10]卿小松,王学文,罗国松,等.载药微球联合TACE治疗原发性肝癌患者的效果观察[J].临床误诊误治,2024,37(12):26-30.
[11]LIU Y,GUO Z,HE W,et al.Study on the nodal composite bearing performance of nontruncated PHC pipe pile and bearing platform[J].Materials,2024,17(13):23.
[12]丁华洋,王兴宇,刘学谦,等.GP73和HSP90α在低浓度甲胎蛋白原发性肝癌诊断中的应用价值[J].安徽医科大学学报,2021,56(8):1291-1294.
[13]胡琳,王钰,舒畅,等.血清miR-599、sMR联合Hsp90α检测对早期原发性肝癌的诊断价值[J].现代生物医学进展,2023,23(1):103-107.
[14]董美衬,白晶,刘海顺,等.血清GPC3、DCP、GP73及AFP联合检测在原发性肝癌的诊断价值[J].标记免疫分析与临床,2022,29(7):1142-1147.
[15]任珊,李伟,潘智玲,等.老年丙肝相关肝癌组织中GS、GPC3蛋白和血清AFP联合检测的临床意义[J].现代肿瘤医学,2022,30(9):1620-1624.
[16]田宇,杨敏,马璇,等.三期动态增强MSCT联合血清AFP、TSGF及AFP-L3检测对原发性肝癌的诊断价值[J].中国CT和MRI杂志,2022,20(10):77-78.
[17]刘莹,陈东妙,王从容.慢性乙型肝炎、乙型肝炎肝硬化和原发性肝癌患者血清腺苷脱氨酶、α-L-岩藻糖苷酶和AFP-L3水平变化及其临床意义探讨[J].实用肝脏病杂志,2023,26(4):552-555.
[18]孙忠怡,孟凡东,隋承光,等.GPC3联合AFP、CEA、CA199检测对肝细胞癌的临床诊断价值[J].中国实验诊断学,2022,26(1):31-34.
[19]CHEN X,CHEN Y,LIANG R,et al.Combination therapy of hepatocellular carcinoma by GPC3-targeted bispecific antibody and irinotecan is potent in suppressing tumor growth in mice[J].Mol Cancer Ther,2022,21(1):149-158.
[20]赖全友,高远,王尚毓,等.MRI联合血清赖氨酸氧化酶样蛋白4、信号转导和转录激活因子3检测用于原发性肝癌诊断的价值[J].陕西医学杂志,2024,53(10):1398-1401,1406.
[21]孟凡岗,刘文宇,甄立军,等.原发性肝癌组织长链非编码RNAJPX、微小RNA-371a-5p表达水平及其与患者术后5年预后关系研究[J].陕西医学杂志,2024,53(8):1130-1134,1138.
[22]CHENARD-POIRIER M,ALMHANNA K,LIM W T,et al.Pharmacokinetics and biomarker analysis from a phase 1/2 open-label study of the anti-GPC3 T-cell engager SAR444200,in patients with advanced solid tumors[J].J Clin Oncol,2024,42(16):2579.
[23]李俊漪,徐剑.龙胆泻肝汤对原发性肝癌肝动脉栓塞化疗术后患者肝功能及肿瘤标志物的影响研究[J].陕西中医,2024,45(10):1353-1356.
[24]周林,肖康,夏建辉.八珍汤加减辅助治疗原发性肝癌疗效及对患者外周血Th17/Treg平衡和不良反应的影响[J].陕西中医,2023,44(9):1216-1219.
[25]ZHANG H,ZHANG L,WU Z.Interaction of STIL with FOXM1 regulates SF3A3 transcription in the hepatocellular carcinoma development[J].Cell Div,2025,20(1):1.
[26]乔轩,杨勇,许涛,等.AFP、AFP-L3及PIVKA-Ⅱ单独及联合检测在早期原发性肝细胞癌中的诊断价值[J].医学研究杂志,2023,52(7):51-55.
相似文献/References:
[1]郭俊霞,魏晓华.乙肝肝硬化患者合并原发性肝癌的危险因素及预后分析*[J].陕西医学杂志,2019,(7):850.
[2]李 珣,张祥林.肝动脉化疗栓塞联合恩替卡韦对原发性肝癌治疗效果及对患者血清中恶性肿瘤特异性生长因子的影响[J].陕西医学杂志,2019,(7):873.
LI Xun,ZHANG Xianglin..Efficacy observation and TSGF change in primary hepatocellular carcinoma by TACE and entecavir[J].,2019,(9):873.
[3]陶 琳.原发性肝癌患者化疗后抗菌药物的应用及继发感染的危险因素分析[J].陕西医学杂志,2023,52(1):89.[doi:DOI:10.3969/j.issn.1000-7377.2023.01.021]
TAO Lin.Application of antibiotics and risk factors of secondary infection in patients with primary liver cancer after chemotherapy[J].,2023,52(9):89.[doi:DOI:10.3969/j.issn.1000-7377.2023.01.021]
[4]刘立友,吴东洋,蔡青山,等.原发性肝癌组织中层粘连蛋白3、黏着斑激酶蛋白表达及其与患者临床病理特征和预后关系研究[J].陕西医学杂志,2023,52(9):1259.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.034]
LIU Liyou,WU Dongyang,CAI Qingshan,et al.Expression of LAMA3 and FAK proteins in primary liver cancer and their relationship with clinicopathological features and prognosis of patients[J].,2023,52(9):1259.[doi:DOI:10.3969/j.issn.1000-7377.2023.09.034]
[5]刘贤国,徐红玉,朱 江.原发性肝癌伴门静脉癌栓产生机制及经导管肝动脉化疗栓塞术联合其他介入方案治疗研究进展[J].陕西医学杂志,2023,52(10):1438.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.036]
LIU Xianguo,XU Hongyu,ZHU Jiang.Research progress on mechanism of thrombus formation of primary liver cancer with portal vein cancer and application progress of TACE combined with other interventional protocols[J].,2023,52(9):1438.[doi:DOI:10.3969/j.issn.1000-7377.2023.10.036]
[6]李晓勤,王 群,何晓兰,等.多模式镇痛对原发性肝癌患者休斯顿疼痛情况调查表评分及血清结合珠蛋白水平的影响[J].陕西医学杂志,2024,(4):475.[doi:DOI:10.3969/j.issn.1000-7377.2024.04.008]
LI Xiaoqin,WANG Qun,HE Xiaolan,et al.InfLuences of multimodal analgesia on HPOI score and serum haptoglobin level in patients with hepatocellular carcinoma[J].,2024,(9):475.[doi:DOI:10.3969/j.issn.1000-7377.2024.04.008]
[7]孟凡岗,刘文宇,甄立军,等.原发性肝癌组织长链非编码RNA JPX、微小RNA-371a-5p表达水平及其与患者术后5年预后关系研究[J].陕西医学杂志,2024,(8):1130.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.027]
MENG Fangang,LIU Wenyu,ZHEN Lijun,et al.Expression levels of long non-coding RNA JPX and microRNA-371a-5p in primary liver cancer tissues and their relationship with 5-year prognosis of patients after surgery[J].,2024,(9):1130.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.027]
[8]罗华权,古代娇,李森林,等.CLEC1B、CCR7、GPSM2在原发性肝癌组织中的表达及临床意义[J].陕西医学杂志,2025,54(9):1259.[doi:DOI:10.3969/j.issn.1000-7377.2025.09.019]
LUO Huaquan,GU Daijiao,LI Senlin,et al.Expression and clinical significance of CLEC1B,CCR7 and GPSM2 in primary liver cancer[J].,2025,54(9):1259.[doi:DOI:10.3969/j.issn.1000-7377.2025.09.019]